BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant 2016; 6(2): 306-313 [PMID: 27358775 DOI: 10.5500/wjt.v6.i2.306] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Schmitz S, Lurje G, Ulmer F, Andert A, Bruners P, Schulze-hagen M, Neumann U, Schoening W. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. Hepatobiliary & Pancreatic Diseases International 2019;18:228-36. [DOI: 10.1016/j.hbpd.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clinics in Liver Disease 2017;21:231-51. [DOI: 10.1016/j.cld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer Med 2017;6:2017-33. [PMID: 28791798 DOI: 10.1002/cam4.1119] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
5 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Reference Citation Analysis]
7 Chang W, Lee JM, Yoon JH, Lee DH, Lee SM, Lee KB, Kim BR, Kim TH, Lee S, Han JK. No-touch radiofrequency ablation using multiple electrodes: An in vivo comparison study of switching monopolar versus switching bipolar modes in porcine livers. PLoS One 2017;12:e0176350. [PMID: 28445542 DOI: 10.1371/journal.pone.0176350] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
8 Martin AN, Wilkins LR, Das D, Johnston LE, Bauer TW, Adams RB, Zaydfudim VM. Efficacy of Radiofrequency Ablation versus Transarterial Chemoembolization for Patients with Solitary Hepatocellular Carcinoma ≤3 cm. The American Surgeon 2019;85:150-5. [DOI: 10.1177/000313481908500220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]